← Leaderboards
Theresa Engel
Leidos Biomedical Research, Inc.
$69,820,225
Attributed
$69,820,225
Total exposure
2
Grants
2
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $54.5M · FY2018–24$100M$75M$50M$25M$0
'18
'19
'20
'21
'22
'23
'24
Funding mix
By agency
NIH$69,820,225 · 2
By mechanism
N01$69,820,225 · 2
Top collaborators
No co-investigators on record.
Most similar at Leidos Biomedical Research, Inc.
Same institution · by research overlap
- David Heimbrook$2,362,140,846
- Barry Gause$4,146,719
- Saliba Katy$6,477,336
- Lori Dodd$9,824,009
Others in their field
Other Emerging Leaders on “Clinical Trials”
- Sonia M Thomas · Research Triangle Institute$700,865,642
- Bambra Strokes · Ppd Development Lp$526,656,217
- Tracy L Nolen · Research Triangle Institute$474,487,152
- Leonard Freedman · Leidos Biomedical Research, Inc.$245,363,765
- Beth Baseler · Leidos Biomedical Research, Inc.$207,964,226
- Ethan Dmitrovsky · Leidos Biomedical Research, Inc.$177,411,785
Research focus
Clinical TrialsVaccinesDosePhase Ii Clinical TrialsMonkeypoxVariantAnimalsAmericanAdvanced DevelopmentBooster VaccineCattleClinical MaterialBirdsCovid-19Age YearsDisease OutbreaksAvian Influenza A VirusCovid-19 VaccineEarly Phase Clinical TrialEvaluationFundingImmunogenicityImmunologicsCovid-19 Booster
Grant awards (6)
Clinical Trails to Evaluate H5N1 Influenza Variant Vaccines$7,985,002
N01 · FY2024 · AI · contact PI
Trial to Evaluate the Immunogenicity of Dose Reduction Strategies of the MVA-BN Mpox Vaccine$6,645,185
N01 · FY2023 · AI · contact PI
Phase 2 COVID-19 Vaccine Variant Clinical Trial$36,854,858
N01 · FY2022 · AI · contact PI
MONKEYPOX VACCINE CLINICAL TRIAL$11,497,606
N01 · FY2022 · AI · contact PI
EARLY PHASE CLINICAL TRIAL TO EVALUATE ANTIVIRALS (APP)$6,142,134
N01 · FY2022 · AI · contact PI
IGF::OT::IGF RESEARCH, DEVELOPMENT, MANUFACTURE OF CLINICAL MATERIALS, AND CLINICAL TESTING OF VACCINES TO PROTECT AGAINST ZIKA VIRUS$695,440
N01 · FY2018 · CA · contact PI